Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Mol Genet Metab. 2016 Oct 15;119(4):295–299. doi: 10.1016/j.ymgme.2016.10.005

Table 2.

Review of Biochemically and HMBS Mutation-Confirmed AIP Cases Reporting Symptoms Before Puberty in the Longitudinal Study of the Porphyrias [13]

Patient Number HMBS Mutation Urine PBG at enrollment* (lab range) Sex AGE AT Recurrent Attacks
Database Enrollment Symptom Onset Menarche
1 c.863_86 4insT 111.5 mg (0–4) F 33 3 12.5 Yes
2 IVS10-2A>G 29 mg/24 hr (<2.4) F 21 3 10 Yes
3 p.R201W 6 mg/g creat (<2.0) F 19 5 9 Yes
4 p.R167Q 13.3 mg/24 hr (0–0.5) F 72 8 16 Yes
5 p.G111R 3.3 mmol/mol creat (0.09–2.97) F 72 9 11 Yes
6 p.R116Q 16.9 mg (0–4) F 41 10 11 Yes
7 p.V267M 5.2 mg (0–4) F 36 10 11 No
8 p.R173W 8.3 mg (0–4) M 53 10 N/A Yes
9 p.A33IV 45 umol/L (0.0–8.8) F 59 11 11 Yes
10 c.633_63 4insC 55.8 mg/g creat (<2.0) F 39 11 11 Yes
11 p.A33IV Not available F 39 13 17 Yes

HMBS: Hydroxylmethylbilane Synthase enzymatic activity (also known as Porphobilinogen Deaminase PBGD)

*

Patients were asymptomatic at the time of enrollment in longitudinal study

PBG: Urine porphobilinogen concentration